Literature DB >> 2497013

Host-parasite interaction in fungal infections.

N Khardori1.   

Abstract

The outcome of host-parasite interactions in fungal infections is determined by the balance between pathogenicity of the organism and the adequacy of the host defenses. A wide variety of host defense mechanisms are involved in protection against fungal infections. These include nonspecific mechanisms such as intact skin and mucus membranes, indigenous microbial flora, and the fungicidal activity of neutrophils and monocytes. Such mechanisms constitute the major host defense against opportunistic fungal infections caused by ubiquitous organisms of low virulence. The effective role of immunoglobulins and complement as opsonins varies with the fungal pathogen involved. Specific immune responses of both the humoral and cell-mediated type develop in response to infections by pathogenic fungi. Antibodies, in general, are not of major importance in protection against these infections. Specifically sensitized T lymphocytes produce lymphokines that activate macrophages. Activated macrophages are the major line of defense against systemic fungal pathogens. The type and degree of impairment in immune responses determines the susceptibility and severity of diseases. The type of immune response also determines the tissue reactions in these diseases and sometimes may be involved in the pathogenesis of the disease process. The role of natural killer cell activity, antibody-dependent cellular cytotoxicity, and biological response modifiers in various fungal infections has been described recently. The microbial factors of importance in fungal infections are adherence, invasion, presence of an antiphagocytic capsule, and ability to grow under altered physiological states of the host. The differences in the virulence of fungal strains is of minor importance in determining the outcome in general. The seriousness of the alteration of the host state rather than the pathogenic properties of the fungus determine the severity of the disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2497013     DOI: 10.1007/bf01963468

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  136 in total

1.  PHYCOMYCOSIS.

Authors:  R SIMON; G G HOFFMAN; H B HARDING
Journal:  Aerosp Med       Date:  1964-07

2.  Subcutaneous and cutaneous mucormycosis and subcutaneous phycomycosis.

Authors:  R D BAKER; J H SEABURY; J D SCHNEIDAU
Journal:  Lab Invest       Date:  1962-11       Impact factor: 5.662

3.  Aspergillus infections in bone marrow transplant recipients.

Authors:  J R Wingard; S U Beals; G W Santos; W G Merz; R Saral
Journal:  Bone Marrow Transplant       Date:  1987-08       Impact factor: 5.483

4.  Induction and expression of cell-mediated immune responses in inbred mice infected with Coccidioides immitis.

Authors:  R A Cox; W Kennell; L Boncyk; J W Murphy
Journal:  Infect Immun       Date:  1988-01       Impact factor: 3.441

5.  Activated neutrophils exhibit enhanced phagocytosis of Cryptococcus neoformans opsonized with normal human serum.

Authors:  T R Kozel; G S Pfrommer; D Redelman
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

6.  Fungal infections complicating acute leukemia.

Authors:  G P Bodey
Journal:  J Chronic Dis       Date:  1966-06

Review 7.  The effect of aging on susceptibility to infection.

Authors:  I D Gardner
Journal:  Rev Infect Dis       Date:  1980 Sep-Oct

8.  Suppressor thymus-derived lymphocytes in fungal infection.

Authors:  J D Stobo; S Paul; R E Van Scoy; P E Hermans
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

9.  Infections after liver transplantation. An analysis of 101 consecutive cases.

Authors:  S Kusne; J S Dummer; N Singh; S Iwatsuki; L Makowka; C Esquivel; A G Tzakis; T E Starzl; M Ho
Journal:  Medicine (Baltimore)       Date:  1988-03       Impact factor: 1.889

10.  Activation of murine polymorphonuclear neutrophils for fungicidal activity with supernatants from antigen-stimulated immune spleen cell cultures.

Authors:  E Brummer; D A Stevens
Journal:  Infect Immun       Date:  1984-08       Impact factor: 3.441

View more
  8 in total

Review 1.  Antifungal proteins.

Authors:  C P Selitrennikoff
Journal:  Appl Environ Microbiol       Date:  2001-07       Impact factor: 4.792

2.  The copper regulon of the human fungal pathogen Cryptococcus neoformans H99.

Authors:  Chen Ding; Jun Yin; Edgar Mauricio Medina Tovar; David A Fitzpatrick; Desmond G Higgins; Dennis J Thiele
Journal:  Mol Microbiol       Date:  2011-08-23       Impact factor: 3.501

3.  Value of detection of antibodies to Candida albicans germ tube in the diagnosis of systemic candidosis.

Authors:  G Quindós; J Pontón; R Cisterna; D W Mackenzie
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-03       Impact factor: 3.267

4.  Systemic candidiasis: an unusual complication of eating mutton.

Authors:  J Bates; C T Dollery; J Cohen; E Schulenburg; J Calam
Journal:  BMJ       Date:  1989-08-26

Review 5.  Aspergillus endocarditis and myocarditis in a patient with the acquired immunodeficiency syndrome (AIDS). A review of the literature.

Authors:  J N Cox; F di Dió; G P Pizzolato; R Lerch; N Pochon
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

Review 6.  Aspergillosis.

Authors:  G P Bodey; S Vartivarian
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

7.  Risk factors for systemic fungal infections in liver transplant recipients.

Authors:  J Briegel; H Forst; B Spill; A Haas; B Grabein; M Haller; E Kilger; K W Jauch; K Maag; G Ruckdeschel
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-05       Impact factor: 3.267

8.  Normally saprobic cryptococci isolated from Cryptococcus neoformans infections.

Authors:  S Krajden; R C Summerbell; J Kane; I F Salkin; M E Kemna; M G Rinaldi; M Fuksa; E Spratt; C Rodriguez; C Rodrigues
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.